Real-world post-authorization effectiveness study (PAES) of pembrolizumab for the treatment of NSCLC across races, ethnicities, and age groups (MK-3475-G18)

Data sources

• Data source(s):
  Other data source
• Data source(s), other:
  Flatiron Health: early non-small cell lung cancer (eNSCLC) Flatiron Health Research Database (FHRD), and advanced non-small cell lung cancer (aNSCLC) FHRD.
• Data sources (types):
  Electronic healthcare records (EHR)

  Non-interventional study

Use of a Common Data Model (CDM)

• CDM mapping:
  No

Data quality specifications

• Check conformance:
  Unknown
• Check completeness:
  Unknown
• Check stability:
  Unknown
• Check logical consistency:
  Unknown

Data characterisation

• Data characterisation conducted:
  Unknown